Growth inhibitory effects of the Diruthenium-Ibuprofen compound, [Ru2Cl(Ibp) 4], in human glioma cells in vitro and in the rat C6 orthotopic glioma in vivo.

about

Diruthenium(ii,iii) metallodrugs of ibuprofen and naproxen encapsulated in intravenously injectable polymer-lipid nanoparticles exhibit enhanced activity against breast and prostate cancer cells.

P2860

Q38662609-DE2266FF-0EE9-45EE-9C00-82A364DFA001

P2860

Growth inhibitory effects of the Diruthenium-Ibuprofen compound, [Ru2Cl(Ibp) 4], in human glioma cells in vitro and in the rat C6 orthotopic glioma in vivo.

Item

http://www.wikidata.org/entity/Q38995385

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Growth inhibitory effects of t ...... C6 orthotopic glioma in vivo.

@en

type

Item

label

Growth inhibitory effects of t ...... C6 orthotopic glioma in vivo.

@en

prefLabel

Growth inhibitory effects of t ...... C6 orthotopic glioma in vivo.

@en

P1476

Growth inhibitory effects of t ...... t C6 orthotopic glioma in vivo

@en

P2093

Fernanda Oliveira Serachi

http://www.w3.org/2001/XMLSchema#string

Iguatinã de M Costa

http://www.w3.org/2001/XMLSchema#string

Marcel Benadiba

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.

Organometallic anticancer compounds

From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study.

Toxicity after radiochemotherapy for glioblastoma using temozolomide--a retrospective evaluation.

Ruthenium antimetastatic agents.

Antitumour metal compounds: more than theme and variations.

Gamma-linolenic acid inhibits both tumour cell cycle progression and angiogenesis in the orthotopic C6 glioma model through changes in VEGF, Flt1, ERK1/2, MMP2, cyclin D1, pRb, p53 and p27 protein expression.

P2888

s00775-014-1143-4

P304

1025-1035

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00775-014-1143-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alison Colquhoun

Denise de Oliveira Silva

Rodrigo L S R Santos

P577

2014-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24824561

http://www.w3.org/2001/XMLSchema#string

Growth inhibitory effects of the Diruthenium-Ibuprofen compound, [Ru2Cl(Ibp) 4], in human glioma cells in vitro and in the rat C6 orthotopic glioma in vivo.

about

P2860

P2860

Growth inhibitory effects of the Diruthenium-Ibuprofen compound, [Ru2Cl(Ibp) 4], in human glioma cells in vitro and in the rat C6 orthotopic glioma in vivo.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698